Do analysts prefer ITRM or NXTC?

NextCure has a consensus target price of $16.50, indicating a potential upside of 777.66%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ITRM or NXTC more profitable?

Iterum Therapeutics' return on equity of 0.00% beat NextCure's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% NextCure N/A -186.96% -124.62%

Do analysts recommend ITRM or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 294.48%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ITRM or CNSP more profitable?

Iterum Therapeutics' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% CNS Pharmaceuticals N/A -238.68% -166.30%

Do analysts recommend ITRM or ACXP?

Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,837.50%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ITRM or ACXP more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Acurx Pharmaceuticals N/A -153.92% -101.69%

Do analysts rate BCAB or ITRM?

BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 4,673.27%. Given BioAtla's stronger consensus rating and higher probable upside, equities analysts clearly believe BioAtla is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BCAB or ITRM more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Iterum Therapeutics N/A N/A -65.54%

Do analysts rate ITRM or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is ITRM or APVO more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Aptevo Therapeutics N/A -198.50% -117.06%

Iterum Therapeutics (ITRM) Competitors

$0.03 0.00 (0.00%)

As of 07/2/2026

Compare

ITRM vs. NXTC, CNSP, ACXP, BCAB, and APVO

Should you buy Iterum Therapeutics stock or one of its competitors? MarketBeat compares Iterum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iterum Therapeutics include NextCure (NXTC), CNS Pharmaceuticals (CNSP), Acurx Pharmaceuticals (ACXP), BioAtla (BCAB), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry.

How does Iterum Therapeutics compare to NextCure?

Iterum Therapeutics (NASDAQ:ITRM) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, NextCure has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

Iterum Therapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A

In the previous week, NextCure had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for NextCure and 0 mentions for Iterum Therapeutics. NextCure's average media sentiment score of 0.49 beat Iterum Therapeutics' score of 0.00 indicating that NextCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
NextCure	Neutral

Iterum Therapeutics' return on equity of 0.00% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
NextCure	N/A	-186.96%	-124.62%

NextCure has a consensus target price of $16.50, indicating a potential upside of 777.66%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Iterum Therapeutics and NextCure tied by winning 7 of the 14 factors compared between the two stocks.

How does Iterum Therapeutics compare to CNS Pharmaceuticals?

Iterum Therapeutics (NASDAQ:ITRM) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Iterum Therapeutics' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 294.48%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CNS Pharmaceuticals has lower revenue, but higher earnings than Iterum Therapeutics. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
CNS Pharmaceuticals	Neutral

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market.

Summary

Iterum Therapeutics and CNS Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Acurx Pharmaceuticals?

Iterum Therapeutics (NASDAQ:ITRM) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Acurx Pharmaceuticals	Neutral

Acurx Pharmaceuticals has lower revenue, but higher earnings than Iterum Therapeutics. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A

Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,837.50%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Iterum Therapeutics' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Iterum Therapeutics has a beta of 2.96, suggesting that its stock price is 196% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.05, suggesting that its stock price is 305% less volatile than the broader market.

Summary

Iterum Therapeutics and Acurx Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 4,673.27%. Given BioAtla's stronger consensus rating and higher probable upside, equities analysts clearly believe BioAtla is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, BioAtla's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
Iterum Therapeutics	Neutral

BioAtla has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Iterum Therapeutics	N/A	N/A	-65.54%

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Iterum Therapeutics has lower revenue, but higher earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Summary

BioAtla and Iterum Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Aptevo Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Iterum Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Iterum Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

In the previous week, Iterum Therapeutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Aptevo Therapeutics	Neutral

Summary

Iterum Therapeutics beats Aptevo Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Iterum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITRM vs. The Competition

Export

Metric	Iterum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.60M	$3.10B	$7.18B	$12.46B
Dividend Yield	N/A	2.05%	2.67%	6.49%
P/E Ratio	-0.04	20.06	27.75	24.70
Price / Sales	4.10	357.05	533.82	98.65
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	-0.20	4.32	10.96	6.46
Net Income	-$24.77M	$64.45M	$3.57B	$337.01M
7 Day Performance	N/A	2.97%	2.11%	1.70%
1 Month Performance	N/A	3.39%	2.80%	0.68%
1 Year Performance	N/A	29.07%	33.40%	23.94%

Iterum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITRM Iterum Therapeutics	0.0217 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
NXTC NextCure	2.4506 of 5 stars	$1.81 +3.4%	$23.00 +1,170.7%	-64.1%	$6.32M	N/A	N/A	90	Gap Down High Trading Volume
CNSP CNS Pharmaceuticals	3.0984 of 5 stars	$4.29 +0.2%	$20.00 +366.2%	-54.1%	$6.27M	N/A	N/A	5
ACXP Acurx Pharmaceuticals	2.3179 of 5 stars	$1.42 -6.0%	$31.00 +2,083.1%	-83.7%	$6.11M	N/A	N/A	3
BCAB BioAtla	1.3826 of 5 stars	$3.57 -1.4%	$200.00 +5,502.2%	-77.9%	$5.93M	$2M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ITRM) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iterum Therapeutics (ITRM) Competitors

ITRM vs. NXTC, CNSP, ACXP, BCAB, and APVO

How does Iterum Therapeutics compare to NextCure?

Summary

How does Iterum Therapeutics compare to CNS Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to Acurx Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to BioAtla?

Summary

How does Iterum Therapeutics compare to Aptevo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iterum Therapeutics (ITRM) Competitors

ITRM vs. NXTC, CNSP, ACXP, BCAB, and APVO

How does Iterum Therapeutics compare to NextCure?

Do institutionals and insiders believe in ITRM or NXTC?

Which has more volatility and risk, ITRM or NXTC?

Which has higher earnings and valuation, ITRM or NXTC?

Does the media refer more to ITRM or NXTC?

Is ITRM or NXTC more profitable?

Do analysts prefer ITRM or NXTC?

Summary

How does Iterum Therapeutics compare to CNS Pharmaceuticals?

Is ITRM or CNSP more profitable?

Do analysts recommend ITRM or CNSP?

Which has preferable earnings & valuation, ITRM or CNSP?

Does the media refer more to ITRM or CNSP?

Do insiders & institutionals have more ownership in ITRM or CNSP?

Which has more volatility and risk, ITRM or CNSP?

Summary

How does Iterum Therapeutics compare to Acurx Pharmaceuticals?

Do insiders and institutionals believe in ITRM or ACXP?

Does the media refer more to ITRM or ACXP?

Which has better valuation and earnings, ITRM or ACXP?

Do analysts recommend ITRM or ACXP?

Is ITRM or ACXP more profitable?

Which has more volatility & risk, ITRM or ACXP?

Summary

How does Iterum Therapeutics compare to BioAtla?

Do analysts rate BCAB or ITRM?

Does the media refer more to BCAB or ITRM?

Which has more risk & volatility, BCAB or ITRM?

Is BCAB or ITRM more profitable?

Do institutionals & insiders have more ownership in BCAB or ITRM?

Which has better earnings & valuation, BCAB or ITRM?

Summary

How does Iterum Therapeutics compare to Aptevo Therapeutics?

Which has more risk and volatility, ITRM or APVO?

Do analysts rate ITRM or APVO?

Is ITRM or APVO more profitable?

Do institutionals and insiders have more ownership in ITRM or APVO?

Which has higher valuation & earnings, ITRM or APVO?

Does the media refer more to ITRM or APVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools